Sofosbuvir/Velpatasvir + Ethinylestradiol/Norgestimate = Unknown or no reaction

Effect on Concentration

Sofosbuvir/Velpatasvir
No change
Applies within class?
No
Ethinylestradiol/Norgestimate
Increase
Applies within class?
No

Pharmacologic Effects

Sofosbuvir/Velpatasvir
Effect
N/A
Applies within class?
No
Ethinylestradiol/Norgestimate
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

The authors state that there is no expected loss of contraceptive efficacy when SOF/VEL is co-administered with a COC containing norgestimate/ethinyl estradiol.

Sources

Sofosbuvir/velpatasvir vs rifampin, ethinylestradiol/norgestimate, or famotidine ^

Study Design

In a phase 1, multiple-dose, randomized, cross-over drug-drug interaction study with 24 healthy individuals, the pharmacokinetics (PK), safety, and tolerability of a once-daily regimen of sofosbuvir 400mg and velpatasvir 100mg (SOF/VEL) were evaluated when co-administered with rifampin 600mg twice-daily.

Study Results

There was no significant change in AUC or Cmax of SOF/VEL when co-administered with the COC. SOF increased the AUC of norgestrel by 19% while VEL increased the Cmax of ethinyl estradiol by 39%.

Study Conclusions

References

E Mogalian, G Shen, L Moorehead, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination. Easl. Barcelona, Spain. ; 2016.